<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        8-483-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PERIOLIMEL N4E emulsion for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLIVE OIL,SOYA OIL,ALANINE,ARGININE,ASPARTIC ACID,GLUTAMIC ACID,GLYCINE,HISTIDINE,ISOLEUCINE5,LEUCINE,METHIONINE,PHENYLALANINE,PROLINE,SERINE,THREONINE,TRYPTOPHAN,TYROSINE,VALINE,SODIUM ACETATE,SODIUM GLYCEROPHOSPHATE,POTASSIUM CHLORIDE,MAGNESIUM CHLORIDE, CALCIUM CHLORIDE,LYSINE,GLUCOSE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30,30,3.66,2.48,0.73,1.26,1.76,1.51,1.26,1.76,1.26,1.76,1.51,1.00,1.26,0.42,0.06,1.62,1.16,1.91,1.19,0.45,0.30,1.99,75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Emulsion for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        748.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Baxalta Belgium Manufacturing SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Baxalta Belgium Manufacturing SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAXTER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B05BA10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PERIOLIMEL is an emulsion for infusion. It is presented in a bag with 3 chambers.</p><p>&nbsp;</p><p>One chamber contains a glucose solution with calcium, the second one contains a lipid emulsion and the third one contains an amino acid solution with other electrolytes.</p><p>&nbsp;</p><p>PERIOLIMEL is used to provide nutrition to adults and children<strong> </strong>&nbsp;greater than 2 years of age by a tube into a vein when normal feeding by mouth is not suitable.</p><p>&nbsp;</p><p>PERIOLIMEL must only be used under medical supervision.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>PERIOLIMEL</strong><strong> N4E emulsion for infusion must not be used:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In premature neonates, infants, and children less than 2 years old.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are hypersensitive (allergic) to egg, soy-bean or peanut proteins or corn/corn products (see also section &ldquo;Warnings and precautions&rdquo; below), or to any other ingredient of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your body has problems using certain amino acids.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an especially high level of fats in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have hyperglycemia (too much sugar in your blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an abnormally high amount of any of the electrolytes (sodium, potassium, magnesium, calcium, and/or phosphorus) in your blood.</p><p>&nbsp;</p><p>In all cases, your doctor will base his/her decision on whether you should receive this medicine on factors such as your age, weight, and medical condition, together with the results of any test performed.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or nurse before PERIOLIMEL is administered to you.</p><p>&nbsp;</p><p>If you are given total parenteral nutrition (TPN) solutions too fast this may result in injury or death.</p><p>&nbsp;</p><p>The infusion must be stopped immediately if any abnormal signs or symptoms of an allergic reaction (such as sweating, fever, chills, headache, skin rashes, or difficulty breathing) develop. This medicinal product contains soy-bean oil and egg phosphatide. Soy-bean and egg proteins may cause hypersensitivity reactions. Cross-allergic reactions between soy-bean and peanut proteins have been observed.</p><p>&nbsp;</p><p>PERIOLIMEL contains glucose derived from corn, which may cause hypersensitivity reactions if you have allergy to corn or corn products (see section &ldquo;PERIOLIMEL N4E, emulsion for infusion must not be used&rdquo; above).</p><p>&nbsp;</p><p>Difficulty breathing could also be a sign that small particles have formed, blocking blood vessels in the lungs (pulmonary vascular precipitates). If you experience any difficulty breathing, tell your doctor or nurse. They will decide a course of action to be taken.</p><p>&nbsp;</p><p>The antibiotic named ceftriaxone must not be mixed or given simultaneously with any calcium containing solutions (including PERIOLIMEL) given to you by a drip into your vein.</p><p>&nbsp;</p><p>These drugs must not be given to you together even via different infusion lines or different infusion sites.</p><p>&nbsp;</p><p>However, you may be given PERIOLIMEL and ceftriaxone sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or were thoroughly flushed with physiological salt solution between the infusions to avoid precipitation (formation of particles of ceftriaxone-calcium salt).</p><p>&nbsp;</p><p>Certain medications and illnesses can increase the risk of developing infection or sepsis (bacteria in the blood). There is a particular risk of infection or sepsis when a tube (intravenous catheter) is placed in your vein. Your doctor will carefully watch you for any signs of infection. Patients who require parenteral nutrition (giving nutrition through a tube in your vein) may be more likely to develop infections from their medical conditions. Using aseptic (&ldquo;germ-free&rdquo;) techniques when placing and caring for the catheter and when making the nutritional formula (TPN) can reduce the risk of infection.</p><p>&nbsp;</p><p>If you are severely malnourished such that you need to receive feedings by vein, your doctor should start the treatment slowly. Also, your doctor should monitor you closely to prevent sudden changes in your fluid, vitamin, electrolyte and mineral levels.</p><p>&nbsp;</p><p>The balance of water and salt in your body and metabolic disorders will be corrected before starting the infusion. Your doctor will monitor your condition while you receive this medicine and may change the dosage or give you additional nutrients, such as vitamins, electrolytes, and trace elements, if he/she feels they are appropriate.</p><p>&nbsp;</p><p>Liver disorders including problems with the elimination of bile (cholestasis), fat storage (hepatic steatosis), fibrosis, possibly leading to hepatic failure, as well as cholecystitis and cholelithiasis have been reported in patients who take intravenous nutrition therapy. The cause of these disorders is thought to be due to multiple factors and may differ between patients. If you suffer from symptoms such as nausea, vomiting, abdominal pain, yellowing of the skin or eyes, consult your doctor in order to allow the identification of possible causative and contributory factors, and possible therapeutic and preventive measures</p><p>&nbsp;</p><p>Your doctor should be aware of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe kidney problem. You also must inform your doctor if you are on dialysis (artificial kidney) or if you have another form of blood cleaning treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe liver problem</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a blood clotting problem</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adrenal glands that are not working properly (adrenal insufficiency). The adrenal glands are triangle-shaped glands located on top of your kidneys</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a build up of water in your body (hyperhydration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not enough water in your body (dehydration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar (diabetes mellitus) that you are not being treated for</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a heart attack or shock due to a sudden heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe metabolic acidosis (when the blood is too acidic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a generalised infection (septicaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coma.</p><p>&nbsp;</p><p>To check the effectiveness and ongoing safety of the administration, your doctor will perform clinical and laboratory tests while you are receiving this medicine. If you are given this medicine for several weeks, your blood will be monitored on a regular basis.</p><p>&nbsp;</p><p>Reduced ability of the body to remove the fats contained in this medicine may result in a &quot;fat overload syndrome&quot; (See Section 4 &ndash; Possible Side Effects).</p><p>&nbsp;</p><p>During the infusion if you notice pain, burning or swelling at the infusion site, or leakage of the infusion, tell your doctor or nurse. The administration will be stopped immediately and restarted in another vein.</p><p>&nbsp;</p><p>If your blood sugar gets too high, your doctor should adjust the rate of PERIOLIMEL<strong> </strong>delivery or give you medication to control your blood sugar (insulin).</p><p>&nbsp;</p><p>PERIOLIMEL<strong> </strong>may be administered via a tube (catheter) into a vein in your arm or a large vein in your chest (central vein).</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>If your child is under 18 years old, special care will be taken to give him/her the correct dosage. Increased precautions will also be taken because of the greater sensitivity of children to the risk of infection. Vitamin and trace element supplementation is always required. Paediatric formulations must be used.</p><p>&nbsp;</p><p><strong>Other medicines and </strong><strong>PERIOLIMEL</strong></p><p>&nbsp;</p><p>Tell your doctor if you are taking or using, have recently taken or used or might take or use any other medicines.</p><p>&nbsp;</p><p>Simultaneous absorption of other medicinal products is not a contraindication, generally. If you take other medicinal products, with or without medical prescription, you should inform your doctor in advance to check compatibility.</p><p>&nbsp;</p><p>Please tell your doctor if you are taking or receiving any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insulin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heparin</p><p>&nbsp;</p><p>PERIOLIMEL<strong> </strong>must not be administered simultaneously with blood through the same infusion tubing.</p><p>&nbsp;</p><p>PERIOLIMEL<strong> </strong>contains calcium. It should not be given together or through the same tube with the antibiotic ceftriaxone because particles may form. If the same device is used to give you successively these medicines, it should be thoroughly rinsed.</p><p>&nbsp;</p><p>Due to the risk of precipitation, PERIOLIMEL<strong> </strong>should not be administered through the same infusion line or admixed together with the antibiotic ampicillin or the antiepileptic fosphenytoin.</p><p>&nbsp;</p><p>The olive and soy-bean oils present in PERIOLIMEL<strong> </strong>contain vitamin K. This does not normally affect blood thinning medicines (anticoagulants) like coumarin. However, if you take anticoagulant medicines you should tell your doctor.</p><p>&nbsp;</p><p>The lipids contained in this emulsion may interfere with the results of certain laboratory tests if the blood sample is taken before the lipids have been eliminated from your bloodstream (these are generally eliminated after a period of 5 to 6 hours without receiving lipids).</p><p>&nbsp;</p><p>PERIOLIMEL<strong> </strong>contains potassium. Special care should be taken in patients taking diuretics, ACE inhibitors, angiotensin II receptor antagonists (drugs for high blood pressure), or immunosuppressants. These types of drugs may increase potassium levels in your blood.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine<s>.</s></p><p><s>&nbsp;</s></p><p>There are no adequate experiences from the use of PERIOLIMEL<strong> </strong>in pregnant or breast-feeding women. PERIOLIMEL<strong> </strong>may be considered during pregnancy and breastfeeding, if necessary. PERIOLIMEL should only be given to pregnant or breast-feeding women after careful consideration</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>&nbsp;</p><p>Not relevant</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dosage</strong></p><p>&nbsp;</p><p>PERIOLIMEL should only be given in adults and children greater than 2 years of age.</p><p>&nbsp;</p><p>It is an emulsion for infusion, to be administered via a tube (catheter) into a vein in your arm or in a large vein in your chest.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>PERIOLIMEL should be at room temperature before use.</p><p>&nbsp;</p><p>PERIOLIMEL is for single use only.</p><p>&nbsp;</p><p>The infusion of 1 bag usually lasts between 12 and 24 hours.</p><p>&nbsp;</p><p><strong>Dosage &ndash; Adults</strong></p><p><strong>&nbsp;</strong></p><p>Your doctor will specify a flow rate corresponding to your needs and clinical condition.</p><p>&nbsp;</p><p>The prescription may be continued for as long as it is needed, depending upon your clinical condition.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Dosage &ndash; Children greater than two years of age and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>The doctor will decide the dose and for how long the medication will be given. This will depend on age, weight, height, medical condition and the ability of the body to break down and use the ingredients in PERIOLIMEL.</p><p>&nbsp;</p><p><strong>If you have been administered more PERIOLIMEL N4E</strong><strong>, emulsion for infusion than you should</strong></p><p><strong>&nbsp;</strong></p><p>If the dose given is too high or the infusion is too fast, the amino acid content may make your blood too acidic, and signs of hypervolaemia (increase of circulating blood volume) may occur. The glucose levels in your blood and urine may increase, hyperosmolar syndrome (excessive blood viscosity) may develop, and the lipid content may increase the level of triglycerides in your blood. Receiving a volume of PERIOLIMEL that is too large may cause nausea, vomiting, chills and electrolyte disturbances. In such situations, the infusion must be stopped immediately.</p><p>&nbsp;</p><p>In some severe cases, your doctor may have to give you temporary renal dialysis to help your kidneys eliminate the excess product.</p><p>&nbsp;</p><p>To prevent these events occurring, your doctor will regularly monitor your condition and test your blood parameters.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you notice any changes in the way you feel during or after the treatment, tell your doctor or nurse right away.</p><p>&nbsp;</p><p>The tests your doctor will perform while you are taking the medicine should minimise the risk of side effects.</p><p>&nbsp;</p><p>If any abnormal signs or symptoms of an allergic reaction develop, such as sweating, fever, chills, headache, skin rashes, or breathing difficulties, the infusion should be stopped immediately.</p><p>&nbsp;</p><p>The following side effects have been reported with PERIOLIMEL:</p><p><strong><em>Frequency - Common: may affect up to 1 in 10 people</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart rate (tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased level of fat in the blood (hypertriglyceridemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure (hypertension)</p><p><em>Frequency - Not known: frequency cannot be estimated from the available data</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reactions including sweating, fever, chills, headache, skin rash (erythematous papular, pustular, macular, generalised rash), itching, hot flush, breathing difficulties</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leakage of the infusion to the surrounding tissue (extravasation) which may result at infusion site level in pain, irritation, swelling/oedema, redness (erythema)/warmth, death of the tissue cells (skin necrosis) or blisters/vesicles, inflammation, thickening or constriction of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&nbsp;</p><p>The following side effects have been reported with similar parenteral nutrition products:</p><p><em>Frequency - Very rare: may affect up to 1 in 10,000 people</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced ability to remove the lipids (fat overload syndrome) associated with sudden and abrupt worsening of the patient&rsquo;s medical condition. The following signs of fat overload syndrome are usually reversible when the lipid emulsion infusion is stopped:</p><p>o&nbsp;&nbsp; Fever</p><p>o&nbsp;&nbsp; Reduction in red blood cells which can make the skin pale and cause weakness or breathlessness (anaemia)</p><p>o&nbsp;&nbsp; Low white blood cell count, which can increase the risk of infection (leukopenia)</p><p>o&nbsp;&nbsp; Low platelet count which can increase the risk of bruising and/or bleeding (thrombocytopenia)</p><p>o&nbsp;&nbsp; Coagulation disorders which effect the ability of the blood to clot</p><p>o&nbsp;&nbsp; High levels of fats in the blood (hyperlipidaemia)</p><p>o&nbsp;&nbsp; Liver fatty infiltration (hepatomegaly)</p><p>o&nbsp;&nbsp; Worsening liver function</p><p>o&nbsp;&nbsp; Central nervous system manifestations (e.g. Coma).</p><p><em>Frequency - Not known: frequency cannot be estimated from the available data</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal blood test results for liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with the elimination of bile (cholestasis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the size of the liver (hepatomegaly)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parenteral nutrition associated liver disease (see &ldquo;Warnings and Precautions&rdquo; in section 2)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Icterus (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of platelets (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased nitrogen levels in the blood (azotemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated liver enzymes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Formation of small particles which may lead to blockage of blood vessels in the lungs (pulmonary vascular precipitates) resulting in pulmonary vascular embolism and difficulty breathing (respiratory distress).</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effect, talk to your doctor or nurse. This includes any possible side effect not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States:</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Store in the overpouch.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date that is stated on the container and the outer packaging (MM/YYYY). The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>PERIOLIMEL N4E</strong><strong>, emulsion for infusion contains</strong></p><p><u>&nbsp;</u></p><p>The active substances for each bag of the reconstituted emulsion are 6.3% (corresponding to 6.3&nbsp;g/100&nbsp;mL) L-amino acid solution (alanine, arginine, glycine, histidine, isoleucine, leucine, lysine (as lysine acetate), methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, aspartic acid, glutamic acid) with electrolytes (sodium, potassium, magnesium, phosphate, acetate, chloride), 15% (corresponding to 15&nbsp;g/100&nbsp;mL) lipid emulsion (refined olive oil and refined soy-bean oil), and 18.75% (corresponding to 18.75&nbsp;g/100&nbsp;mL) glucose solution (as glucose monohydrate) with calcium.</p><p>&nbsp;</p><p>The other ingredients are:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:586px"><tbody><tr><td style="vertical-align:top"><p>Lipid emulsion</p><p>compartment</p></td><td style="vertical-align:top"><p>Amino acid solution</p><p>compartment</p></td><td style="vertical-align:top"><p>Glucose solution</p><p>compartment</p></td></tr><tr><td style="vertical-align:top"><p>Purified egg phosphatide, glycerol, sodium oleate, sodium hydroxide (for pH adjustment), water for injection</p></td><td style="vertical-align:top"><p>Glacial acetic acid (for pH adjustment), water for injection</p></td><td style="vertical-align:top"><p>Hydrochloric acid (for pH adjustment), water for injection</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What PERIOLIMEL N4E, emulsion for infusion looks like and contents of the pack

PERIOLIMEL is an emulsion for infusion packaged in a 3-compartment bag. One compartment contains a lipid emulsion, another compartment an amino acid solution with electrolytes and the third compartment a glucose solution with calcium. These compartments are separated by nonpermanent seals. Before administration, the content of the compartments need to be mixed by rolling the bag onto itself, starting at the top of the bag until the peal seal is open. 

Appearance prior to reconstitution:
-	The amino acid and glucose solutions are clear, colourless, or slightly yellow.
-	The lipid emulsion is homogenous with a milky appearance.

Appearance after reconstitution: homogeneous milk-like emulsion.

The 3-compartment bag is a multilayer plastic bag. The inner (contact) layer of the bag material is designed to be compatible with the constituents and authorised additives. 

To prevent contact with oxygen contained in the air, the bag is packaged in an oxygen barrier overpouch with an oxygen absorber sachet.

Pack sizes

1,000 mL bag: 1 carton with 6 bags
1,500 mL bag: 1 carton with 4 bags
2,000 mL bag: 1 carton with 4 bags
2,500 mL bag: 1 carton with 2 bags

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>BAXTER S.A.</strong></p><p>BOULEVARD RENE BRANQUART, 80</p><p>7860 LESSINES</p><p>BELGIUM</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">PERIOLIMEL هو مستحلب للتسريب الوريدي. وهو يتوفر في كيس يحتوي على 3 أقسام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي إحدى الحجرات على محلول الجلوكوز مع الكالسيوم، وتحتوي الثانية على مستحلب دهني، بينما تحتوي الثالثة على محلول حمض أميني مع سوائل إلكترولايت أخرى.</p><p dir="RTL">يُستعمل PERIOLIMEL لتوفير الغذاء للبالغين والأطفال الأكبر من سنتين من العمر من خلال أنبوب في الوريد عندما تكون التغذية العادية عن طريق الفم غير مناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُستعمل PERIOLIMEL إلا تحت إشرافٍ طبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم استعمال مستحلب </strong><strong>PERIOLIMEL N4E</strong><strong> </strong><strong>للتسريب الوريدي</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع حديثي الولادة المبتسرين والرضع والأطفال الأقل من عامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط التحسس (الحساسية) للبيض أو فول الصويا أو بروتينات الفول السوداني السوداني أو منتجات الذرة / الذرة (انظر أيضًا قسم &quot;التحذيرات والاحتياطات&quot; أدناه) ، أو لأي مكون آخر من هذا الدواء (مدرج في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان جسمك يعاني من مشاكل في استعمال أحماض أمينية معينة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان مستوى الدهون في الدم لديك عاليًا للغاية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط السكر في الدم (ارتفاع في مستوى السكر في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك كمية عالية بشكل غير طبيعي من أي من سوائل الإلكترولايت (الصوديوم، والبوتاسيوم، والمغنيسيوم، والكالسيوم، والفوسفور أو أي منها) في دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في جميع الحالات، سوف يستند طبيبك في قراره بشأن ما إذا كان يجب إعطاؤك هذا الدواء على عوامل مثل عمرك ووزنك وحالتك الطبية، بالإضافة إلى نتائج أي اختبار تم إجراؤه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">استشر طبيبك أو الممرضة قبل تلقي العلاج بمستحضر PERIOLIMEL.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم إعطاؤك محاليل تغذية شاملة بالحقن (TPN) على عجلة ودون تريث، فقد ينتج عن ذلك التعرض للإصابة أو الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إيقاف التسريب الوريدي فورًا في حالة ظهور أي علامات أو أعراض غير طبيعية للتفاعلات التحسسية (مثل التعرق أو الحمى أو القشعريرة أو الصداع أو الطفح الجلدي أو صعوبة التنفس). يحتوي هذا المستحضر الطبي على زيت فول الصويا وفوسفاتيد البيض. قد تتسبب بروتينات فول الصويا والبيض في ردود فعل فرط التحسس. وقد لوحظت ردود فعل تحسسية مشتركة بين بروتينات فول الصويا والفول السوداني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي PERIOLIMEL على الجلوكوز المشتق من الذرة ، والذي قد يسبب تفاعلات فرط الحساسية إذا كان لديك حساسية من الذرة أو منتجات الذرة (انظر قسم &quot;يجب عدم استخدام مستحلب PERIOLIMEL N4E للتسريب الوريدي&quot; أعلاه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد تكون صعوبة التنفس أيضًا علامة على تكون الجسيمات الصغيرة، مما قد يؤدي إلى انسداد الأوعية الدموية في الرئتين (الرواسب الوعائية الرئوية). إذا واجهت أي صعوبة في التنفس، فتحدث إلى طبيبك أو الممرضة. وسوف يقررون بدورهم مسار العمل الذي يتعين اتخاذه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم خلط المضاد الحيوي المسمى سيفترياكسون أو إعطائه في آنٍ واحد مع أية محاليل تحتوي على الكالسيوم تُعطى لك عن طريق التنقيط في الوريد (بما في ذلك PERIOLIMEL).</p><p dir="RTL">يجب عدم إعطائك هذه الأدوية معًا حتى إذا كانت عبر أنابيب تسريب وريدي مختلفة أو في مواضع تسريب مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ومع ذلك، يجوز إعطاؤك PERIOLIMEL وسيفترياكسون واحدًا تلو الآخر إذا تم استعمال خطوط التسريب الوريدي في مواضع مختلفة أو إذا تم استبدال خطوط التسريب الوريدي أو غسلها جيدًا بمحلول ملحي فيزيولوجي بين التسريبات الوريدية لتجنب الترسب (تكون جزيئات من ملح كالسيوم السيفترياكسون).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تزيد بعض الأدوية والأمراض من خطر الإصابة بالعدوى أو الإنتان (البكتيريا في الدم). هناك خطر معين من العدوى أو الإنتان عندما يتم وضع أنبوب (قسطرة في الوريد) في وريدك. سوف يلاحظك طبيبك بعناية بحثًا عن أي علامات للعدوى. المرضى الذين يحتاجون إلى التغذية بالحقن (إعطاء التغذية اللازمة عبر أنبوب في وريدك) قد يكونون أكثر عرضة للإصابة بالعدوى بفعل حالاتهم الطبية. يمكن أن يقلل استعمال أساليب التعقيم (&quot;الخالية من الجراثيم&quot;) عند وضع القسطرة والاعتناء بها وعند وضع النظام الغذائي (التغذية الشاملة بالحقن (TPN)) من خطر العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من سوء حاد في التغذية يستدعي تلقي التغذية عن طريق الوريد، يجب أن يبدأ طبيبك العلاج ببطء. ويجب أيضًا أن يلاحظك طبيبك عن قرب لمنع التغيرات المفاجئة في مستويات السوائل والفيتامينات والإلكترولايت والمعادن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم تصحيح توازن الماء والملح في الجسم والاضطرابات الاستقلابية (التمثيل الغذائي) قبل البدء في إجراء التسريب الوريدي. وسيقوم طبيبك بملاحظة حالتك أثناء تلقي هذا الدواء وقد يغير الجرعة أو يعطيك عناصر غذائية إضافية، مثل الفيتامينات وسوائل الإلكترولايت والعناصر الزهيدة المقدار، إذا شعر بأنها مناسبة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن اضطرابات الكبد بما في ذلك مشاكل التخلص من الصفراء (الركود الصفراوي) ، وتخزين الدهون (التنكس الدهني الكبدي) ، والتليف ، الذي من المحتمل أن يؤدي إلى فشل كبدي ، وكذلك التهاب المرارة وتحص صفراوي في المرضى الذين يتناولون العلاج بالتغذية الوريدية. يُعتقد أن سبب هذه الاضطرابات ناتج عن عوامل متعددة وقد يختلف بين المرضى. إذا كنت تعاني من أعراض مثل الغثيان والقيء وآلام البطن واصفرار الجلد أو العينين ، فاستشر طبيبك للسماح بتحديد العوامل المسببة والمساهمة المحتملة والتدابير العلاجية والوقائية الممكنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يكون طبيبك على علم بأي مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة حادة في الكلى. كما يجب عليك إبلاغ طبيبك إذا كنت تخضع للغسيل الكلوي (الكلى الاصطناعية) أو إذا كنت تتلقى نوعًا آخر من أنواع علاج تنظيف الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة حادة في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة تجلط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغدد الكظرية التي لا تعمل بشكل صحيح (قصور الغدة الكظرية). الغدد الكظرية هي عبارة عن غدد على شكل مثلث توجد على قمة كليتيك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض رئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم الماء في الجسم (فَرْطُ التَّمَيُّه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الماء في الجسم (الجفاف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم (داء السكري) دون تلقي علاج لهذه الحالة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية أو صدمة بسبب القصور المفاجئ للقلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحماض الاستقلابي الشديد (عندما يكون الدم شديد الحموضة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى معممة (إنتان دموي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غيبوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للتحقق من الفعالية والسلامة المستمرة للدواء الذي يتم إعطاؤه لك، سيقوم الطبيب بإجراء فحوصات سريرية ومخبرية أثناء تلقيك لهذا الدواء. إذا تم إعطاؤك هذا الدواء لعدة أسابيع، فستتم ملاحظة دمك على أساس منتظم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي انخفاض قدرة الجسم على إزالة الدهون الموجودة في هذا الدواء إلى &quot;متلازمة الدهون الزائدة&quot; (انظر القسم 4 - الآثار الجانبية المحتملة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أثناء التسريب الوريدي ألمًا أو حرقًا أو تورمًا في موضع التسريب الوريدي أو ترشحًا في التسريب الوريدي؛ فيُرجى إبلاغ طبيبك أو الممرضة. سيتم إيقاف إعطاء الدواء على الفور وإعادة إعطائه في وريد آخر.</p><p dir="RTL">في حالة ارتفاع مستوى السكر في الدم لديك بدرجة كبيرة، يجب على طبيبك تعديل معدل ضخ مستحضر PERIOLIMEL عبر الوريد أو إعطاؤك دواءً للتحكم في مستوى السكر في الدم (الأنسولين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء PERIOLIMEL عبر أنبوب (قسطرة) يتم تركيبه في وريدٍ في الذراع أو وريدٍ كبير في الصدر (الوريد مركزي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">إذا كان عمر طفلك أقل من 18 عامًا، فسيتم إيلاء عناية خاصة لمنحه الجرعة الصحيحة. كما سيتم اتخاذ احتياطات متزايدة بسبب الحساسية الأكبر في الأطفال لخطر الإصابة بالعدوى. وسيتطلب دائمًا توافر مكملات الفيتامين والعناصر الزهيدة. ويجب استعمال التراكيب المخصوصة للأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعاطي الأدوية الأخرى مع </strong><strong>PERIOLIMEL</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تستعمل، أو تناولت أو استعملت مؤخرًا، أو قد تتناول أو تستعمل مستقبلاً أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بشكل عام، لا يعد التناول المتزامن للمستحضرات الطبية الأخرى من الموانع. ولكن إذا كنت تتناول مستحضرات طبية أخرى، بوصفة طبية أو بدون، يجب عليك إبلاغ طبيبك مسبقا للتحقق من التوافق الكيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى ابلاغ طبيبك إذا كنت تاخذ &nbsp;أيًا مما يلي:</p><ul><li dir="RTL">الأنسولين</li><li dir="RTL">الهيبارين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم إعطاء PERIOLIMEL في آنٍ واحد مع الدم من خلال أنبوب التسريب الوريدي ذاته.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي PERIOLIMEL على الكالسيوم. لذلك لا ينبغي إعطاؤه مع المضاد الحيوي &quot;سيفترياكسون&quot; أو من خلال نفس الأنبوب لاحتمال تكون الجسيمات. إذا تم استعمال نفس الجهاز لإعطائك هذه الأدوية تباعًا، يجب غسله وتنظيفه جيدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لخطر الترسيب ، لا ينبغي إعطاء PERIOLIMEL من خلال نفس خط التسريب أو خلطه مع المضاد الحيوي أمبيسلين أو فوسفينيتوين المضاد للصرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل من زيت الزيتون وزيت فول الصويا المتواجدين في PERIOLIMEL على فيتامين ك. وهذا عادةً لا يؤثر على أدوية ترقيق الدم (مضادات التخثر) مثل كومارين. بالرغم من ذلك، إذا كنت تتناول أدوية مضادة للتخثر، ينبغي عليك إخبار طبيبك.</p><p dir="RTL">قد تتداخل الدهون الموجودة في هذا المستحلب مع نتائج بعض الاختبارات المعملية إذا تم أخذ عينة الدم قبل التخلص من الدهون من مجرى الدم (يتم التخلص منها عادة بعد فترة من 5 إلى 6 ساعات دون تلقي الدهون).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي PERIOLIMEL على البوتاسيوم. يجب توخي الحذر مع المرضى الذين يتناولون الأدوية المدرة للبول، ومثبطات الإنزيم المحول للأنجيوتنسين، ومضادات مستقبلات الأنجيوتنسين 2 (أدوية ضغط الدم المرتفع)، أو مثبطات المناعة. قد تزيد هذه الأنواع من الأدوية مستويات البوتاسيوم في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين طبيعيًا، أو تظنين بأنكِ قد تكونين حاملاً أو تخططين لإنجاب طفل، فيُرجى استشارة طبيبكِ قبل تعاطي<br />&nbsp;هذا الدواء<s>.</s></p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL">لا توجد تجارب كافية من استخدام PERIOLIMEL في النساء الحوامل أو المرضعات. يمكن اعتبار PERIOLIMEL أثناء الحمل والرضاعة الطبيعية ، إذا لزم الأمر. يجب إعطاء PERIOLIMEL فقط للنساء الحوامل أو المرضعات بعد دراسة متأنية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>السياقة واستعمال الماكنات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا ينطبق</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُستعمل PERIOLIMEL إلا للبالغين والأطفال الأكبر من سنتين من العمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا الدواء هو عبارة عن مستحلب للتسريب الوريدي يتم إعطاؤه عبر أنبوب (قسطرة) في وريدٍ في الذراع أو وريدٍ كبير في الصدر.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">يجب أن يكون PERIOLIMEL في درجة حرارة الغرفة قبل الاستعمال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستعمل PERIOLIMEL مرة واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يدوم التسريب الوريدي لكيس واحد عادة ما بين 12 و24 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة </strong><strong>&ndash; </strong><strong>للبالغين</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">سيقوم طبيبك بتحديد معدل التدفق بما يتوافق مع احتياجاتك وحالتك السريرية.</p><p dir="RTL">قد تستمر الوصفة الطبية طالما كانت هناك حاجة إليها، وهذا يتوقف على حالتك السريرية.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong>الجرعة </strong><strong>&ndash; </strong><strong>للأطفال الأكبر من عامين والمراهقين</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">سيقرر الطبيب الجرعة ومدة إعطاء الدواء. سيعتمد ذلك على العمر والوزن والطول والحالة الطبية وقدرة الجسم على تحليل مكونات PERIOLIMEL والاستفادة منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تعاطي جرعات من مستحلب </strong><strong>PERIOLIMEL</strong><strong> </strong><strong>للتسريب الوريدي</strong><strong> </strong><strong>أكثر من المقررة لك</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كانت الجرعة الممنوحة لك عالية للغاية أو نسب التسريب الوريدي سريعة جدًا، فقد يعمل محتوى الأحماض الأمينية على تحويل الدم إلى حمض عالي التركيز، وقد تظهر علامات فرط حجم الدم (زيادة حجم الدم في الدورة الدموية). قد تزداد مستويات الجلوكوز في الدم والبول، وقد تحدث متلازمة فرط الأسمولية (فرط لزوجة الدم)، وقد يؤدي محتوى الدهون إلى زيادة مستوى الدهون الثلاثية في الدم. يؤدي تلقي جرعة كبيرة للغاية من PERIOLIMEL إلى الغثيان والقيء والارتجاف واضطرابات في سوائل الإلكترولايت. عند حدوث هذه الأعراض، يجب إيقاف التسريب الوريدي فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في بعض الحالات الشديدة، قد يضطر طبيبك إلى إجراء غسيل كلوي مؤقت لك لمساعدة الكليتين على التخلص من الدواء الزائد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لمنع حدوث هذه الحالات، سيقوم طبيبك بملاحظة حالتك بانتظام وإجراء اختبار لمؤشرات الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استعمال هذا الدواء، فيُرجى طرحها على طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا الدواء مثل جميع الأدوية في حدوث آثار جانبية، بالرغم من عدم تعرض جميع المرضى لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرضة على الفور إذا لاحظت أي تغييرات في حالتك أثناء تعاطي العلاج أو بعد تعاطيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تقلل الاختبارات التي سيجريها طبيبك أثناء تعاطيك للدواء من مخاطر الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إيقاف التسريب الوريدي فورًا في حالة ظهور أي علامات أو أعراض غير طبيعية للإصابة بردود الفعل التحسسية مثل التعرق أو الحمى أو القشعريرة أو الصداع أو الطفح الجلدي أو صعوبات التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حدثت الآثار الجانبية التالية لدى المرضى الذين يتلقون العلاج بمستحضر PERIOLIMEL:</p><p dir="RTL"><strong><em>معدل التكرار - شائعة: قد تحدث لدى ما يصل إلى شخص واحد من كل </em></strong><strong><em>10</em></strong><strong><em> أشخاص</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة في معدل نبضات القلب (تسارع القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقصان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الدهون في الدم (فرط الدهون الثلاثية في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضغط الدم (ارتفاع ضغط الدم)</p><p dir="RTL"><em>معدل التكرار - غير معروفة: لا يمكن تقدير معدل تكرارها من البيانات المتاحة</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية وتشمل تعرق ، حمى ، قشعريرة ، صداع ، طفح جلدي (حمامي ، حطاطي ، بثري ، بقعي ، طفح جلدي معمم) ، حكة ، تدفق ساخن ، صعوبات في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتشاح في موضع التسريب الوريدي إلى الأنسجة المحيطة (تسرب) والذي يمكن أن يتسبب على مستوى موضع التسريب الوريدي في حدوث ألم أو تهيج أو تورم/وذمة أو احمرار (حمامية)/دفء أو موت خلايا الأنسجة (نخر الجلد) أو بثور/حويصلات ، التهاب ، سماكة أو انقباض الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&nbsp;</p><p dir="RTL">حدثت الآثار الجانبية التالية لدى المرضى الذين يتلقون أدوية التغذية بالحقن المماثلة:</p><p dir="RTL"><em>معدل التكرار - نادرة جدًا: قد تحدث لدى ما يصل إلى شخص واحد من كل </em><em>10000</em><em> شخص</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض القدرة على إزالة الدهون (متلازمة الدهون الزائدة) المرتبطة بالتدهور المفاجئ والسريع للحالة الطبيبة للمريض. عادة ما تكون العلامات التالية لمتلازمة الدهون الزائدة قابلة للعلاج عند إيقاف التسريب الوريدي لمستحلب الدهون:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم الحمراء والذي قد يجعل البشرة شاحبة اللون ويتسبب في ضعف أو ضيق التنفس<br />&nbsp;(فقر الدم)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كرات الدم البيضاء، مما يزيد من خطر العدوى (نقص في عدد كرات الدم البيضاء)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية التي يمكن أن تزيد من خطر حدوث الكدمات ونزيف أو كليهما معًا<br />(نقص الصفيحات)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات التخثر التي تؤثر على قدرة الدم على التجلط</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الدهون في الدم (فرط الشحميات)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتشاح دهون الكبد (ضَخامَةُ الكَبِد)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور وظائف الكبد</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مظاهر تتعلق بالجهاز العصبي المركزي (مثل الغيبوبة).</p><p dir="RTL"><em>معدل التكرار - غير معروفة: لا يمكن تقدير معدل تكرارها من البيانات المتاحة</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج اختبار الدم غير طبيعية في وظيفة الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في إزالة الصفرة (رُكودٌ صَفْراوِيّ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في حجم الكبد (تضخم الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغذية الوريدية المصاحبة لأمراض الكبد (انظر &quot;التحذيرات والاحتياطات&quot; في القسم 2)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان&rlm;&lrm; (الصفرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدموية (نقص الصفيحات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات النيتروجين في الدم (آزوتيمية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع انزيمات الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون جسيمات صغيرة قد تتسبب في انسداد الأوعية الدموية في الرئتين (الرواسب الوعائية الرئوية) مما يؤدي إلى انسداد الأوعية الدموية الرئوية وصعوبة التنفس (الضائقة التنفسية).</p><p dir="RTL"><em>&nbsp;</em></p><p>&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا ظهرت عليك أي آثار جانبية، فيُرجى التحدث إلى طبيبك أو الممرضة. ويتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. كما يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً (انظر التفاصيل أدناه). يمكنك المساعدة في تقديم مزيد من المعلومات حول سلامة هذا الدواء، عن طريق الإبلاغ عن الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:603px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:603px"><tbody><tr><td><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الرجاء التصال بالجهات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تجمد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزن في الكيس المُقوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الحاوية والتغليف الخارجي (شهر/سنة). يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عبر مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات مستحلب </strong><strong>PERIOLIMEL N4E</strong><strong> </strong><strong>للتسريب الوريدي</strong><strong> </strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">المواد الفعالة لكل كيس من مستحلب المستحضر هي 6.3% (بما يعادل 6.3 غم/100 مل) محلول الحمض الأميني-إل<br />(ألانين وأرجينين وجلايسين وهستيدين وأيزوليوسين وليوسين ولايسين (كلايسين أسيتات) ومثيونين وفينيل ألانين وبرولين وسيرين وثريونين وتربتوفان وتيروسين وفالين وحمض الأسبارتيك وجلوتاميت) مع سوائل الإلكترولايت (صوديوم وبوتاسيوم ومغنيسيوم وفوسفات وأسيتات وكلوريد) و15% (بما يعادل 15 غم/100 مل) مستحلب دهني (عبارة عن زيت زيتون وزيت فول الصويا مكررين) و18.75% (بما يعادل 18.75 غم/100 مل) محلول جلوكوز (كجلوكوز أحادي الهيدرات) مع الكالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:586px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">قسم المستحلب الدهني</p></td><td style="vertical-align:top"><p dir="RTL">قسم محلول الحمض قسم</p></td><td style="vertical-align:top"><p dir="RTL">قسم محلول الجلوكوز</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فوسفاتيد البيض المنقى، الجلسرين، أُوليئات الصوديوم، هيدروكسيد الصوديوم (لتعديل الرقم الهيدروجيني)، ماء للحقن</p></td><td style="vertical-align:top"><p dir="RTL">حمض الأسيتيك الجليدي (لتعديل الرقم الهيدروجيني)، ماء للحقن</p></td><td style="vertical-align:top"><p dir="RTL">حامض الهيدروكلوريك (لتعديل الرقم الهيدروجيني)، ماء للحقن</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل مستحلب </strong><strong>PERIOLIMEL N4E</strong><strong> </strong><strong>للتسريب الوريدي ومحتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">PERIOLIMEL هو مستحلب للتسريب الوريدي معبأ في كيس من 3 أقسام. يحتوي أحد الأقسام على مستحلب للدهون، والثاني على محلول الحمض الأميني مع سوائل الإلكترولايت، بينما يحتوي الثالث على محلول الجلوكوز مع الكالسيوم. تفصل بين هذه الأقسام سدادات غير دائمة. قبل إعطاء الدواء، يجب خلط محتويات الأقسام عن طريق تقليب الكيس على نفسه، بدءًا من الجزء العلوي من الكيس حتى تُفتح السدادة الفاصلة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المظهر قبل إعادة التكوين</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون محاليل الأحماض الأمينية والجلوكوز إما رائقة أو عديمة اللون أو مصفرة قليلاً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتجانس مستحلب الدهون مع مظهر حليبي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المظهر بعد إعادة التكوين</strong><strong>:</strong> مستحلب متجانس شبيه بالحليب.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">يعتبر الكيس ذو الأقسام الثلاثة كيسًا بلاستيكيًا متعدد الطبقات. صُممت الطبقة الداخلية (المتلامسة) من مواد الأكياس لتكون متوافقة مع المكونات والمضافات المرخص بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لمنع التلامس مع الأوكسجين الموجود في الهواء، يُغلف الكيس في كيس مقوى حاجز للأكسجين مع كيس لامتصاص الأوكسجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أحجام العبوات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">كيس 1000 مل: عبوة كرتونية بها 6 أكياس</p><p dir="RTL">كيس 1500 مل: عبوة كارتونية بها 4 أكياس</p><p dir="RTL">كيس 2000 مل: عبوة كارتونية بها 4 أكياس</p><p dir="RTL">كيس 2500 مل: عبوة كارتونية بها &nbsp;2كيسان</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تُطرح جميع أحجام العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr" style="text-align:left"><strong>BAXTER S.A.</strong></p><p dir="ltr" style="text-align:left">BOULEVARD RENE BRANQUART, 80</p><p dir="ltr" style="text-align:left">7860 LESSINES</p><p dir="ltr" style="text-align:left">BELGIUM</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PERIOLIMEL N4E, emulsion for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PERIOLIMEL is presented in the form of a 3-compartment bag. 

Each bag contains a glucose solution with calcium, a lipid emulsion and an amino acid solution with other electrolytes.
	                                                                                                                                Contents per bag
	                                                                                                        1,000 mL	1,500 mL	2,000 mL	2,500 mL
18.75% Glucose solution 
(corresponding to 18.75 g/100 mL)                                                     400 mL  	 600 mL	          800 mL	1,000 mL
6.3% Amino acid solution 
(corresponding to 6.3 g/100 mL)	                                                      400 mL	  600 mL	  800 mL	1,000 mL
15% Lipid emulsion 
(corresponding to 15 g/100 mL)	                                                       200 mL	   300 mL          400 mL	500 mL

Composition of the reconstituted emulsion after mixing the contents of the 3 compartments:

Active substances	                                             1,000 mL    	1,500 mL	2,000 mL	2,500 mL
Refined olive oil + refined soy-bean oil*	              30.00 g	         45.00 g	         60.00 g	         75.00 g
Alanine	                                                                      3.66 g	           5.50 g	         7.33 g	         9.16 g
Arginine                                                                 	2.48 g	           3.72 g	         4.96 g      	6.20 g
Aspartic acid	                                                        0.73 g	           1.10 g	         1.46 g	        1.83 g
Glutamic acid	1.26 g	1.90 g	2.53 g	3.16 g
Glycine	1.76 g	2.63 g	3.51 g	4.39 g
Histidine	1.51 g	2.26 g	3.02 g	3.77 g
Isoleucine	1.26 g	1.90 g	2.53 g	3.16 g
Leucine	1.76 g	2.63 g	3.51 g	4.39 g
Lysine (equivalent to lysine acetate)	1.99 g(2.81 g)	2.99 g(4.21 g)	3.98 g(5.62 g)	4.98 g(7.02 g)
Methionine	1.26 g	1.90 g	2.53 g	3.16 g
Phenylalanine	1.76 g	2.63 g	3.51 g	4.39 g
Proline	1.51 g	2.26 g	3.02 g	3.77 g
Serine	1.00 g	1.50 g	2.00 g	2.50 g
Threonine	1.26 g	1.90 g	2.53 g	3.16 g
Tryptophan	0.42 g	0.64 g	0.85 g	1.06 g
Tyrosine	0.06 g	0.10 g	0.13 g	0.16 g
Valine	1.62 g	2.43 g	3.24 g	4.05 g
Sodium acetate, trihydrate	1.16 g	1.73 g	2.31 g	2.89 g
Sodium glycerophosphate, hydrated	1.91 g	2.87 g	3.82 g	4.78 g
Potassium chloride	1.19 g	1.79 g	2.38 g	2.98 g
Magnesium chloride, hexahydrate	0.45 g	0.67 g	0.90 g	1.12 g
Calcium chloride, dihydrate	0.30 g	0.44 g	0.59 g	0.74 g
Glucose  (equivalent to glucose monohydrate)	75.00 g(82.50 g)	112.50 g(123.75 g)	150.00 g(165.00 g)	187.50g(206.25 g)
*: Mixture of refined olive oil (approximately 80%) and refined soy-bean oil (approximately 20%) corresponding to a ratio essential fatty acids / total fatty acids of 20%.


For the full list of excipients, see section 6.1.

Nutritional intakes of reconstituted emulsion for each of the bag sizes:

                   1,000 mL	1,500 mL 	2,000 mL	2,500 mL
Lipids		30 g		45 g		60 g		75 g
Amino acids 		25.3 g		38.0 g		50.6 g		63.3 g
Nitrogen 		4.0 g		6.0 g		8.0 g		10.0 g
Glucose 		75.0 g		112.5 g		150.0 g		187.5 g
Energy:				
Total calories approx. 		700 kcal		1,050 kcal		1,400 kcal		1,750 kcal
    Non-protein calories		600 kcal		900 kcal		1,200 kcal		1,500 kcal
    Glucose calories 		300 kcal		450 kcal		600 kcal		750 kcal
    Lipid calories*		300 kcal		450 kcal		600 kcal		750 kcal
				
    Non-protein calories / nitrogen ratio 		150 kcal/g		150 kcal/g		150 kcal/g		150 kcal/g
    Glucose / lipid calories ratio		50/50		50/50		50/50		50/50
    Lipid / total calories 		43%		43%		43%		43%
Electrolytes:				
    Sodium 		21.0 mmol		31.5 mmol		42.0 mmol		52.5 mmol
    Potassium 		16.0 mmol		24.0 mmol		32.0 mmol		40.0 mmol
    Magnesium 		2.2 mmol		3.3 mmol		4.4 mmol		5.5 mmol
    Calcium 		2.0 mmol		3.0 mmol		4.0 mmol		5.0 mmol
    Phosphate**		8.5 mmol		12.7 mmol		17.0 mmol		21.2 mmol
    Acetate 		27 mmol		41 mmol		55 mmol		69 mmol
    Chloride		24 mmol		37 mmol		49 mmol		61 mmol
pH 		6.4	6.4	6.4	6.4
Osmolarity 		760 mosm/L		760 mosm/L		760 mosm/L		760 mosm/L
*: Includes calories from purified egg phosphatide
**: Includes phosphate provided by the lipid emulsion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution:
Emulsion for infusion.

Appearance prior to reconstitution:
-	The amino acids and glucose solutions are clear, colourless or slightly yellow, 
-	The lipid emulsion is homogenous with a milky appearance.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PERIOLIMEL is indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>PERIOLIMEL is not recommended for use in children less than 2 years of age due to inadequate composition and volume (see sections 4.4; 5.1 and 5.2).</p><p>&nbsp;</p><p>The maximum daily dose mentioned below should not be exceeded. Due to the static composition of the multi-chamber bag, the ability to simultaneously meet all nutrient needs of the patient may not be possible. Clinical situations may exist where patients require amounts of nutrients varying from the composition of the static bag. In this situation any volume (dose) adjustments must take into consideration the resultant effect this will have on the dosing of all other nutrient components of PERIOLIMEL.</p><p>&nbsp;</p><p>In adults</p><p>The dosage depends on the patient&rsquo;s energy expenditure, clinical status, body weight, and the ability to metabolise the constituents of PERIOLIMEL, as well as additional energy or proteins provided orally/enterally; therefore, the bag size should be chosen accordingly.</p><p>&nbsp;</p><p>The average daily requirements are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.16 to 0.35&nbsp;g nitrogen /kg&nbsp;body&nbsp;weight (1 to 2&nbsp;g of amino acids/kg), depending on the patient&#39;s nutritional status and degree of catabolic stress,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 to 40&nbsp;kcal/kg,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 to 40&nbsp;mL fluid /kg, or 1 to 1.5&nbsp;mL per expended kcal.</p><p>&nbsp;</p><p>For PERIOLIMEL, the maximal daily dose is defined by fluid intake, 40&nbsp;mL/kg, corresponding to 1&nbsp;g/kg amino acids, 3&nbsp;g/kg glucose, 1.2&nbsp;g/kg lipids, 0.8&nbsp;mmol/kg sodium, and 0.6&nbsp;mmol/kg potassium. For a 70&nbsp;kg patient, this would be equivalent to 2,800&nbsp;mL PERIOLIMEL per day, resulting in an intake of 71&nbsp;g amino acids, 210&nbsp;g glucose, and 84&nbsp;g lipids (i.e., 1,680&nbsp;non-protein kcal and 1,960&nbsp;total kcal).</p><p>&nbsp;</p><p>Normally, the flow rate must be increased gradually during the first hour and then be adjusted to take into account the dose being administered, the daily volume intake, and the duration of the infusion.</p><p>&nbsp;</p><p>For PERIOLIMEL, the maximal infusion rate is 3.2&nbsp;mL/kg/hour, corresponding to 0.08&nbsp;g/kg/hour amino acids, 0.24&nbsp;g/kg/hour glucose, and 0.10&nbsp;g/kg/hour lipids.</p><p>&nbsp;</p><p>In children greater than 2 years of age and adolescents</p><p>&nbsp;</p><p>There have been no studies performed in the paediatric population.</p><p><em><u>&nbsp;</u></em></p><p>The dosage depends on the patient&rsquo;s energy expenditure, clinical status, body weight, and the ability to metabolise constituents of PERIOLIMEL, as well as additional energy or proteins given orally/enterally; therefore, the bag size should be chosen accordingly.</p><p>&nbsp;</p><p>In addition, daily fluid, nitrogen, and energy requirements continuously decrease with age. Two groups, ages 2 to 11 years and 12 to 18 years, are considered.</p><p>&nbsp;</p><p>For PERIOLIMEL, in both age groups, the magnesium concentration is the limiting factor for daily dose. In the 2 to 11 year age group, the lipid concentration is the limiting factor for hourly rate. In the 12 to 18 year age group, the glucose concentration is the limiting factor for hourly rate. The resulting intakes are displayed below:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Constituent</strong></p></td><td colspan="2"><p><strong>2 to 11 years</strong></p></td><td colspan="2"><p><strong>12 to 18 years</strong></p></td></tr><tr><td><p>Recommended<sup>a</sup></p></td><td><p>PERIOLIMEL Max Vol</p></td><td><p>Recommended<sup>a</sup></p></td><td><p>PERIOLIMEL Max Vol</p></td></tr><tr><td colspan="5"><p><strong>Maximum Daily Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fluids (mL/kg/d)</p></td><td><p>60 &ndash; 120</p></td><td><p>45</p></td><td><p>50 &ndash; 80</p></td><td><p>45</p></td></tr><tr><td style="vertical-align:top"><p>Amino acids (g/kg/d)</p></td><td><p>1 &ndash; 2 (up to 2.5)</p></td><td><p>1.1</p></td><td><p>1 &ndash; 2</p></td><td><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Glucose (g/kg/d)</p></td><td><p>1.4 &ndash; 8.6</p></td><td><p>3.4</p></td><td><p>0.7 &ndash; 5.8</p></td><td><p>3.4</p></td></tr><tr><td style="vertical-align:top"><p>Lipids (g/kg/d)</p></td><td><p>0.5 &ndash; 3</p></td><td><p>1.4</p></td><td><p>0.5 &ndash; 2 (up to 3)</p></td><td><p>1.4</p></td></tr><tr><td style="vertical-align:top"><p>Total energy (kcal/kg/d)</p></td><td><p>30&ndash; 75</p></td><td><p>31.5</p></td><td><p>20 &ndash; 55</p></td><td><p>31.5</p></td></tr><tr><td colspan="5"><p><strong>Maximum Hourly Rate</strong></p></td></tr><tr><td style="vertical-align:top"><p>PERIOLIMEL (mL/kg/h)</p></td><td><p>&nbsp;</p></td><td><p>4.3</p></td><td><p>&nbsp;</p></td><td><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>Amino acids (g/kg/h)</p></td><td><p>0.20</p></td><td><p>0.11</p></td><td><p>0.12</p></td><td><p>0.08</p></td></tr><tr><td style="vertical-align:top"><p>Glucose (g/kg/h)</p></td><td><p>0.36</p></td><td><p>0.33</p></td><td><p>0.24</p></td><td><p>0.24</p></td></tr><tr><td style="vertical-align:top"><p>Lipids (g/kg/h)</p></td><td><p>0.13</p></td><td><p>0.13</p></td><td><p>0.13</p></td><td><p>0.10</p></td></tr></tbody></table><p>a: Recommended values from 2018 ESPGHAN/ESPEN/ESPR Guidelines</p><p>&nbsp;</p><p>Normally, the flow rate must be increased gradually during the first hour and then be adjusted to take into account the dose being administered, the daily volume intake, and the duration of the infusion.</p><p>&nbsp;</p><p>In general, it is recommended to start the infusion for small children with low daily dose and gradually increase it up to the maximal dosage (see above).</p><p>&nbsp;</p><p>Method and duration of administration</p><p>For single use only.</p><p>&nbsp;</p><p>It is recommended that, after opening the bag, the contents are used immediately and not stored for subsequent infusion.</p><p>&nbsp;</p><p>After reconstitution, the mixture is homogenous with a milky appearance.</p><p>&nbsp;</p><p>For instructions for preparation and handling of the emulsion for infusion, see section 6.6.</p><p>&nbsp;</p><p>Due to its low osmolarity, PERIOLIMEL can be administered through a peripheral or central vein.</p><p>&nbsp;</p><p>The recommended duration of infusion for a parenteral nutrition bag is between 12 and 24 hours.</p><p>&nbsp;</p><p>Treatment with parenteral nutrition may be continued for as long as required by the patient&rsquo;s clinical conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The use of PERIOLIMEL is contraindicated in the following situations:
-	In premature neonates, infants, and children less than 2 years of age,
-	Hypersensitivity to egg, soy-bean, or peanut proteins, or corn/corn products (see section 4.4.), or to any of the active substances or excipients, listed in section 6.1,
-	Congenital abnormalities of amino acid metabolism,
-	Severe hyperlipidaemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia,
-	Severe hyperglycemia, 
-	Pathologically-elevated plasma concentrations of sodium, potassium, magnesium, calcium, and/or phosphorus.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An excessively fast administration of total parenteral nutrition (TPN) solutions may result in severe or fatal consequences.</p><p>&nbsp;</p><p>The infusion must be stopped immediately if any signs or symptoms of an allergic reaction (such as sweating, fever, chills, headache, skin rashes, or dyspnea) develop. This medicinal product contains soy-bean oil, and egg phosphatide. Soy-bean and egg proteins may cause hypersensitivity reactions. Cross-allergic reactions between soy-bean and peanut proteins have been observed.</p><p>&nbsp;</p><p>PERIOLIMEL contains glucose derived from corn which may cause hypersensitivity reactions in patients with allergy to corn or corn products (see section 4.3).</p><p>&nbsp;</p><p>Ceftriaxone must not be mixed or administered simultaneously with any calcium-containing IV solutions even via different infusion lines or different infusion sites. Ceftriaxone and calcium-containing solutions may be administered sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation. In patients requiring continuous infusion with calcium-containing TPN solutions, healthcare professionals may wish to consider the use of alternative antibacterial treatments which do not carry a similar risk of precipitation. If use of ceftriaxone is considered necessary in patients requiring continuous nutrition, TPN solutions and ceftriaxone can be administered simultaneously, albeit via different infusion lines at different sites. Alternatively, infusion of TPN solution could be stopped for the period of ceftriaxone infusion, considering the advice to flush infusion lines between solutions (see sections 4.5 and 6.2).</p><p>&nbsp;</p><p>Pulmonary vascular precipitates causing pulmonary vascular embolism and respiratory distress have been reported in patients receiving parenteral nutrition. In some cases, fatal outcomes have occurred. Excessive addition of calcium and phosphate increases the risk of formation of calcium phosphate precipitates (see section 6.2).</p><p>&nbsp;</p><p>Suspected precipitate formation in the blood stream has also been reported.</p><p>&nbsp;</p><p>In addition to inspection of the solution, the infusion set and catheter should also periodically be checked for precipitates.</p><p>&nbsp;</p><p>If signs of respiratory distress occur, the infusion should be stopped and medical evaluation initiated.</p><p>&nbsp;</p><p>Do not add other medicinal products or substances to any components of the bag or to the reconstituted emulsion without first confirming their compatibility and the stability of the resulting preparation (in particular, the stability of the lipid emulsion).</p><p>&nbsp;</p><p>Formation of precipitates or destabilization of the lipid emulsion could result in vascular occlusion (see sections 6.2 and 6.6).</p><p>&nbsp;</p><p>Severe water and electrolyte equilibration disorders, severe fluid overload states, and severe metabolic disorders must be corrected before starting the infusion.</p><p>&nbsp;</p><p>Specific clinical monitoring is required when an intravenous infusion is started.</p><p>&nbsp;</p><p>Vascular-access infection and sepsis are complications that may occur in patients receiving parenteral nutrition, particularly in case of poor maintenance of catheters, immunosuppressive effects of illness or drugs. Careful monitoring of signs, symptoms, and laboratory test results for fever/chills, leukocytosis, technical complications with the access device, and hyperglycemia can help recognize early infections. Patients who require parenteral nutrition are often predisposed to infectious complications due to malnutrition and/or their underlying disease state. The occurrence of septic complications can be decreased with heightened emphasis on aseptic techniques in catheter placement and maintenance, as well as aseptic techniques in the preparation of the nutritional formula.</p><p>&nbsp;</p><p>Monitor water and electrolyte balance, serum osmolarity, serum triglycerides, acid/base balance, blood glucose, liver and kidney function tests, coagulation tests, and blood count, including platelets, throughout treatment.</p><p>&nbsp;</p><p>Elevated liver enzymes and cholestasis have been reported with similar products. Monitoring of serum ammonia should be considered if hepatic insufficiency is suspected.</p><p>&nbsp;</p><p>Metabolic complications may occur if the nutrient intake is not adapted to the patient&#39;s requirements, or the metabolic capacity of any given dietary component is not accurately assessed. Adverse metabolic effects may arise from administration of inadequate or excessive nutrients or from inappropriate composition of an admixture for a particular patient&#39;s needs.</p><p>&nbsp;</p><p>Administration of amino acid solutions may precipitate acute folate deficiency; folic acid is, therefore, recommended to be given daily.</p><p>&nbsp;</p><p><u>Extravasation</u></p><p>Catheter site should be monitored regularly to identify signs of extravasation.&nbsp;</p><p>&nbsp;</p><p>If extravasation occurs the administration should be stopped immediately, keeping the inserted catheter or cannula in place for immediate management of the patient. If possible, aspiration should be performed through the inserted catheter/ cannula in order to reduce the amount of fluid present in the tissues before removing the catheter/ cannula. When involving an extremity, the concerned limb should be elevated.</p><p>&nbsp;</p><p>Depending on the extravasated product (including the product(s) being mixed with PERIOLIMEL, if applicable) and the stage/extent of any injury, appropriate specific measures should be taken. Options for management may include non-pharmacologic, pharmacologic and/or surgical intervention. In case of large extravasation, plastic surgeon advice should be sought within the first 72 hours.</p><p>&nbsp;</p><p>The extravasation site should be monitored at least every 4 hours during the first 24 hours, then once daily</p><p>&nbsp;</p><p>The infusion should not be restarted in the same peripheral or central vein.</p><p><u>&nbsp;</u></p><p><u>Hepatic Insufficiency</u></p><p>Use with caution in patients with hepatic insufficiency because of the risk of developing or worsening neurological disorders associated with hyperammonaemia. Regular clinical and laboratory tests are required, particularly liver function parameters, blood glucose, electrolytes and triglycerides.</p><p>&nbsp;</p><p><u>Renal Insufficiency</u></p><p>Use with caution in patients with renal insufficiency, particularly if hyperkalaemia is present, because of the risk of developing or worsening metabolic acidosis and hyperazotemia if extra-renal waste removal is not being performed. Fluid, triglycerides and electrolyte status should be closely monitored in these patients.</p><p>&nbsp;</p><p><u>Hematologic</u></p><p>Use with caution in patients with coagulation disorders and anaemia. Blood count and coagulation parameters should be closely monitored.</p><p>&nbsp;</p><p><u>Endocrine and Metabolism</u></p><p>Use with caution in patients with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolic acidosis. Administration of carbohydrates is not recommended in the presence of lactic acidosis. Regular clinical and laboratory tests are required.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes mellitus. Monitor glucose concentrations, glucosuria, ketonuria and, where applicable adjust insulin dosages.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperlipidaemia due to the presence of lipids in the emulsion for infusion. Regular clinical and laboratory tests are required.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amino acid metabolism disorders.</p><p>&nbsp;</p><p><u>Hepatobiliary disorders </u></p><p>Hepatobiliary disorders including cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure, as well as cholecystitis and cholelithiasis are known to develop in some patients on parenteral nutrition. The etiology of these disorders is thought to be multifactorial and may differ between patients. Patients developing abnormal laboratory parameters or other signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.</p><p>&nbsp;</p><p>Serum triglyceride concentrations and the ability of the body to remove lipids must be checked regularly.</p><p>&nbsp;</p><p>Serum triglyceride concentrations must not exceed 3<u>&nbsp;</u>mmol/L during the infusion.</p><p>&nbsp;</p><p>If a lipid metabolism abnormality is suspected, it is recommended to measure daily serum triglyceride levels after a period of 5 to 6 hours without administering lipids. In adults, the serum must be clear in less than 6 hours after stopping the infusion containing the lipid emulsion. The next infusion must only be administered when the serum triglyceride concentrations have returned to baseline values.</p><p>&nbsp;</p><p>Fat overload syndrome has been reported with similar products. The reduced or limited ability to metabolise the lipids contained in PERIOLIMEL may result in a &quot;fat overload syndrome&quot; which may be caused by overdose; however, the signs and symptoms of this syndrome may also occur when the product is administered according to instructions (see also section 4.8).</p><p>&nbsp;</p><p>In the event of hyperglycemia, the infusion rate of PERIOLIMEL must be adjusted and/or insulin administered.</p><p>&nbsp;</p><p>Thrombophlebitis may develop if peripheral veins are used. The catheter insertion site must be monitored daily for local signs of thrombophlebitis.</p><p>&nbsp;</p><p>When making additions, the final osmolarity of the mixture must be measured before administration. The mixture obtained must be administered through a central or peripheral venous line depending on its final osmolarity. If the final mixture administered is hypertonic, it may cause irritation of the vein when administered into a peripheral vein.</p><p>&nbsp;</p><p>Although there is a natural content of trace elements and vitamins in the product, the levels are insufficient to meet body requirements, and these should be added to prevent deficiencies from developing. See instructions for making additions to this product.</p><p>&nbsp;</p><p>Caution should be exercised in administering PERIOLIMEL to patients with increased osmolarity, adrenal insufficiency, heart failure or pulmonary dysfunction.</p><p>&nbsp;</p><p>In malnourished patients, initiation of parenteral nutrition can precipitate fluid shifts resulting in pulmonary oedema and congestive heart failure, as well as a decrease in the serum concentration of potassium, phosphorus, magnesium, or water-soluble vitamins. These changes can occur within 24 to 48 hours; therefore, careful and slow initiation of parenteral nutrition is recommended together with close monitoring and appropriate adjustments of fluid, electrolytes, trace elements, and vitamins.</p><p>&nbsp;</p><p>Do not connect bags in series in order to avoid the possibility of air embolism due to residual gas contained in the primary bag.</p><p>&nbsp;</p><p>To avoid risks associated with excessively rapid infusion rates, it is recommended to use a continuous and controlled infusion.</p><p>&nbsp;</p><p>PERIOLIMEL must be administered with caution to patients with a tendency towards electrolyte retention.</p><p>&nbsp;</p><p>Intravenous infusion of amino acids is accompanied by increased urinary excretion of trace elements, in particular copper and zinc. This should be taken into account in the dosing of trace elements, especially during long-term intravenous nutrition.</p><p>&nbsp;</p><p><u>Interference with laboratory tests</u></p><p>The lipids contained in this emulsion may interfere with the results of certain laboratory tests (see section 4.5).</p><p>&nbsp;</p><p><u>Special precautions in paediatrics</u></p><p>When administered to children greater than 2 years of age, it is essential to use a bag that has a volume corresponding to the daily dosage.</p><p>&nbsp;</p><p>PERIOLIMEL is not suitable for use in children less than 2 years of age because:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The glucose intake is too low, leading to a low glucose / lipid ratio,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The absence of cysteine makes the amino acid profile inadequate,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calcium is too low,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The bag volumes are not appropriate.</p><p>&nbsp;</p><p>Maximal infusion rate is 4.3 mL/kg/hour in children 2 to 11 years of age and 3.2 mL/kg/hour in children 12 to 18 years of age.</p><p>&nbsp;</p><p>Vitamin and trace elements supplementation is always required. Paediatric formulations must be used.</p><p>&nbsp;</p><p><u>Geriatric population</u></p><p>In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p><p>PERIOLIMEL must not be administered simultaneously with blood through the same infusion tubing because of the possibility of pseudoagglutination.</p><p>&nbsp;</p><p>The lipids contained in this emulsion may interfere with the results of certain laboratory tests (for example, bilirubin, lactate dehydrogenase, oxygen saturation, blood haemoglobin) if the blood sample is taken before the lipids are eliminated (these are generally eliminated after a period of 5 to 6 hours without receiving lipids).</p><p>&nbsp;</p><p>Precipitation of ceftriaxone-calcium can occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing intravenous solutions, including PERIOLIMEL, through the same infusion line (e.g., via Y-site). However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see sections 4.4 and 6.2).</p><p>&nbsp;</p><p>PERIOLIMEL contains vitamin K, naturally present in lipid emulsions. The amount of vitamin K in recommended doses of PERIOLIMEL are not expected to influence effects of coumarin derivatives.</p><p>&nbsp;</p><p>Due to the potassium content of PERIOLIMEL, special care should be taken in patients treated with potassium-sparingdiuretics (e.g., amiloride, spironolactone, triamterene), angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus or cyclosporine in view of the risk of hyperkalemia.</p><p>&nbsp;</p><p>Some medicinal products, like insulin, may interfere with the body&rsquo;s lipase system. This kind of interaction seems, however, to be of limited clinical importance.</p><p>&nbsp;</p><p>Heparin given in clinical doses causes a transient release of lipoprotein lipase into the circulation. This may result initially in increased plasma lipolysis followed by a transient decrease in triglyceride clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no clinical data from the use of PERIOLIMEL in pregnant women. No animal reproductive studies have been performed with PERIOLIMEL (see section 5.3). Taking into account the use and indications of PERIOLIMEL, the product may be considered during pregnancy, if necessary. PERIOLIMEL should only be given to pregnant women after careful consideration.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There is insufficient information on the excretion of PERIOLIMEL components/metabolites in human milk. Parenteral nutrition may become necessary during breast-feeding. PERIOLIMEL should only be given to breast-feeding women after careful consideration.</p><p>&nbsp;</p><p><u>Fertility </u></p><p>No adequate data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potential undesirable effects may occur as a result of inappropriate use (for example: overdose, excessively fast infusion rate) (see sections 4.4 and 4.9).</p><p>&nbsp;</p><p>At the beginning of the infusion, any of the following abnormal signs (sweating, fever, shivering, headache, skin rashes, dyspnoea) should be cause for immediate discontinuation of the infusion:</p><p>&nbsp;</p><p>The adverse drug reactions (ADRs) reported with OLIMEL N9 in a randomized, double-blind, active-controlled, efficacy and safety study, are listed in the table below. Twenty-eight patients with various medical conditions (i.e., postsurgical fasting, severe malnutrition, enteral intake insufficient or forbidden) were included and treated; patients in the OLIMEL group received drug product up to 40&nbsp;mL/kg/d over 5 days.</p><p>&nbsp;</p><p>The pooled data from clinical trials and the postmarketing experience indicate the following adverse drug reactions (ADRs) related to PERIOLIMEL.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>MedDRA Preferred Term</strong></p></td><td><p><strong>Frequency<sup>a</sup></strong></p></td></tr><tr><td><p>Immune System Disorders</p></td><td><p>Hypersensitivity reactions including hyperhidrosis, pyrexia, chills, headache, skin rash (erythematous, papular, pustular, macular, generalised rash), pruritus, hot flush, dyspnoea</p></td><td><p>Not known<sup>b</sup></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Cardiac Disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridemia</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Not known<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Extravasation which may result at infusion site level in: pain, irritation, swelling/oedema, erythema/warmth, skin necrosis, blisters/vesicles, inflammation, induration, skin tightness</p></td><td style="vertical-align:top"><p>Not known<sup>b</sup></p></td></tr></tbody></table><p>a: Frequency is defined as very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge;&nbsp;1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); or not known (cannot be estimated from the available data).</p><p>b: ADRs reported during post-marketing experience with PERIOLIMEL</p><p>&nbsp;</p><p>The following class-like-adverse drug reactions (ADRs) have been described in other sources in relation to similar parenteral nutrition products; the frequency of these events is not known.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood and Lymphatic System Disorders: Thrombocytopenia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatobiliary Disorders: Cholestasis, Hepatomegaly, Jaundice</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immune System Disorders: Hypersensitivity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injury, poisoning and procedural complications: Parenteral nutrition associated liver disease (see section 4.4, sub-section &ldquo;Hepatobiliary disorders&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investigations: Blood alkaline phosphatase increased, Transaminases increased, Blood bilirubin increased, Elevated liver enzymes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal and Urinary Disorders: Azotemia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vascular disorders: Pulmonary vascular precipitates (pulmonary vascular embolism and respiratory distress) (see section 4.4)</p><p>&nbsp;</p><p><u>Fat overload syndrome (very rare)</u></p><p>Fat overload syndrome has been reported with similar products. This may be caused by inappropriate administration (e.g. overdose and/or infusion rate higher than recommended, see section 4.9); however, the signs and symptoms of this syndrome may also occur at the start of an infusion when the product is administered according to instructions. The reduced or limited ability to metabolize the lipids contained in PERIOLIMEL accompanied by prolonged plasma clearance may result in a &ldquo;fat overload syndrome&rdquo;. This syndrome is associated with a sudden deterioration in the patient&rsquo;s clinical condition and is characterized by findings such as fever, anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, liver fatty infiltration (hepatomegaly), deteriorating liver function, and central nervous system manifestations (e.g. coma). The syndrome is usually reversible when infusion of the lipid emulsion is stopped.</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States:</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of inappropriate administration (overdose and/or infusion rate higher than recommended), signs of hypervolaemia and acidosis may occur.</p><p>&nbsp;</p><p>An excessively fast infusion or administration of an inappropriately large volume of the product may cause nausea, vomiting, chills and electrolyte disturbances. In such situations the infusion must be stopped immediately.</p><p>&nbsp;</p><p>Hyperglycaemia, glucosuria, and a hyperosmolar syndrome may develop if glucose infusion rate exceeds clearance.</p><p>&nbsp;</p><p>The reduced or limited ability to metabolise lipids may result in a &quot;fat overload syndrome&quot;, the results of which are usually reversible after the infusion of the lipid emulsion is stopped (see also section 4.8).</p><p>&nbsp;</p><p>In some serious cases, haemodialysis, haemofiltration or haemodiafiltration may be necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Solutions for parenteral nutrition/combinations</p><p><strong>ATC code: </strong>B05 BA10.</p><p>&nbsp;</p><p>PERIOLIMEL&rsquo;s content in nitrogen (L series amino acids) and energy (glucose and triglycerides) enables maintaining an adequate nitrogen/energy balance.</p><p>&nbsp;</p><p>This formulation also contains electrolytes.</p><p>&nbsp;</p><p>The lipid emulsion included in PERIOLIMEL is an association of refined olive oil and refined soy-bean oil (ratio 80/20), with the following approximate distribution of fatty acids:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15% saturated fatty acids (SFA)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65% monounsaturated fatty acids (MUFA)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20% polyunsaturated essential fatty acids (PUFA)</p><p>&nbsp;</p><p>The phospholipid/triglyceride ratio is 0.06.</p><p>&nbsp;</p><p>Olive oil contains significant amounts of alpha-tocopherol which, combined with a moderate PUFA intake, contribute to improved vitamin E status and the reduction of lipid peroxidation.</p><p>&nbsp;</p><p>The amino acid solution contains 17 L-series amino acids (including 8 essential amino acids), which are required for protein synthesis.</p><p>&nbsp;</p><p>Amino acids also represent an energy source. Their oxidation results in excretion of nitrogen in the form of urea.</p><p>&nbsp;</p><p>The amino acid<em> </em>profile is as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Essential amino acids/total amino acids: 44.8%</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Essential amino acids (g)/total nitrogen (g): 2.8%</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Branched-chain amino acids/total amino acids: 18.3%</p><p>&nbsp;</p><p>The carbohydrate source is glucose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ingredients of PERIOLIMEL (amino acids, electrolytes, glucose and lipids) are distributed, metabolised and removed in the same way as if they had been administered individually.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No preclinical studies with PERIOLIMEL have been performed.</p><p>&nbsp;</p><p>Preclinical toxicity studies performed using the lipid emulsion contained in PERIOLIMEL have identified the changes, which are conventionally found with a high intake of a lipid emulsion: fatty liver, thrombocytopaenia and elevated cholesterol.</p><p>&nbsp;</p><p>Preclinical studies performed using the solutions of amino acids and glucose contained in PERIOLIMEL of different qualitative compositions and concentrations have not, however, revealed any specific toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Lipid emulsion compartment:</u></p><p>Purified egg phosphatide, Glycerol, Sodium oleate, Sodium hydroxide (for pH adjustment), Water for injections.</p><p>&nbsp;</p><p><u>Compartment of amino-acid solution with electrolytes:</u></p><p>Glacial acetic acid (for pH adjustment), Water for injections.</p><p>&nbsp;</p><p><u>Compartment of glucose solution with calcium:</u></p><p>Hydrochloric acid (for pH adjustment), Water for injections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not add other medicinal products or substances to any components of the bag or to the reconstituted emulsion without first confirming their compatibility and the stability of the resulting preparation (in particular, the stability of the lipid emulsion).</p><p>&nbsp;</p><p>Incompatibilities may be produced, for example, by excessive acidity (low pH) or inappropriate content of divalent cations (Ca<sup>2+ </sup>and Mg<sup>2+</sup>), which may destabilize the lipid emulsion.</p><p>&nbsp;</p><p>As with any parenteral nutrition admixture, calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium phosphate precipitates.</p><p>&nbsp;</p><p>PERIOLIMEL contains calcium ions which pose additional risk of coagulation precipitated in citrate anticoagulated/preserved blood or components.</p><p>&nbsp;</p><p>Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions, including PERIOLIMEL, through the same infusion line (e.g., via Y-connector) because of the risk of precipitation of ceftriaxone-calcium salt (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p>Due to the risk of precipitation, PERIOLIMEL should not be administered through the same infusion line or admixed together with ampicillin or fosphenytoin.</p><p>&nbsp;</p><p>Check compatibility with solutions administered simultaneously through the same administration set, catheter, or cannula.</p><p>&nbsp;</p><p>Do not administer before, simultaneously with, or after blood through the same equipment because of the risk of pseudoagglutination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years if the overwrap is not damaged.

After reconstitution
It is recommended that the product be used immediately after the non-permanent seals between the 3 compartments have been opened. However, the stability of the reconstituted emulsion has been demonstrated for 7 days (between 2°C and 8°C) followed by 48 hours at temperature not exceeding 25°C.

After addition of supplements (electrolytes, trace elements and vitamins; see section 6.6)
For specific admixtures, in-use stability has been demonstrated for 7 days (between 2°C and 8°C) followed by 48 hours at temperature not exceeding 25°C.

From a microbiological point of view, any admixture should be used immediately. If not used immediately, storage times and conditions, after mixing and prior to use, are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless addition of supplements has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p><p>Do not freeze.</p><p>Store in the overpouch.</p><p>For storage conditions of the reconstituted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The 3-compartment bag is a multilayer plastic bag. The inner (contact) layer of the bag material is made of a blend of polyolefinic copolymers and is compatible with amino acid solutions, glucose solutions, and lipid emulsions. Other layers are made of polyethylene vinyl acetate (EVA), and of copolyester.</p><p>&nbsp;</p><p>The glucose compartment is fitted with an injection site to be used for addition of supplements.</p><p>&nbsp;</p><p>The amino acid compartment is fitted with an administration site for insertion of the spike of the infusion set.</p><p>&nbsp;</p><p>The bag is packaged in an oxygen barrier overpouch with an oxygen absorber sachet.</p><p>&nbsp;</p><p><u>Pack sizes:</u></p><p>1,000&nbsp;mL bag: 1 carton with 6 bags</p><p>1,500&nbsp;mL bag: 1 carton with 4 bags</p><p>2,000&nbsp;mL bag: 1 carton with 4 bags</p><p>2,500&nbsp;mL bag: 1 carton with 2 bags</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To open</p><p>Remove the protective overpouch.</p><p>&nbsp;</p><p>Discard the oxygen absorber / oxygen indicator sachet.</p><p>&nbsp;</p><p>Confirm the integrity of the bag and of the nonpermanent seals. Use only if the bag is not damaged; if the nonpermanent seals are intact (i.e., no mixture of the contents of the 3 compartments); if the amino acid solution and the glucose solution are clear, colourless, or slightly yellow, and practically free of visible particles; and if the lipid emulsion is a homogeneous liquid with a milky appearance.</p><p>&nbsp;</p><p>Mixing the solutions and the emulsion</p><p>Ensure that the product is at room temperature when breaking the nonpermanent seals.</p><p>&nbsp;</p><p>Manually roll the bag onto itself, starting at the top of the bag (hanger end). The nonpermanent seals will disappear from the side near the inlets. Continue to roll the bag until the seals are open along approximately half of their length.</p><p>&nbsp;</p><p>Mix by inverting the bag at least 3 times.</p><p>&nbsp;</p><p>After reconstitution, the mixture is a homogeneous emulsion with a milky appearance.</p><p>&nbsp;</p><p>Additions</p><p>The capacity of the bag is sufficient to enable additions such as vitamins, electrolytes, and trace elements.</p><p>&nbsp;</p><p>Any additions (including vitamins) may be made into the reconstituted mixture (after the nonpermanent seals have been opened and after the contents of the 3 compartments have been mixed).</p><p>&nbsp;</p><p>Vitamins may also be added into the glucose compartment before the mixture is reconstituted (before opening the nonpermanent seals and before mixing the 3 compartments).</p><p>&nbsp;</p><p>When making additions to formulations containing electrolytes, the amount of electrolytes already present in the bag should be taken into account.</p><p>&nbsp;</p><p>Additions must be performed by qualified personnel under aseptic conditions.</p><p>&nbsp;</p><p>PERIOLIMEL may be supplemented with electrolytes according to the tables below:</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Per 1,000&nbsp;mL</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Included level</strong></p></td><td style="vertical-align:top"><p><strong>Maximal further addition</strong></p></td><td style="vertical-align:top"><p><strong>Maximal total level</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sodium</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 129&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150&nbsp;mmol</p></td></tr><tr><td style="vertical-align:top"><p>Potassium</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 134&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150&nbsp;mmol</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.2&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.4&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.6&nbsp;mmol</p></td></tr><tr><td style="vertical-align:top"><p>Calcium</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.0&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.0&nbsp;(1.5<sup>a</sup>)&nbsp;mmol</p></td><td style="vertical-align:top"><p>5.0&nbsp;(3.5<sup>a</sup>)&nbsp;mmol</p></td></tr><tr><td style="vertical-align:top"><p>Inorganic Phosphate</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.0&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.0&nbsp;mmol</p></td></tr><tr><td style="vertical-align:top"><p>Organic Phosphate</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8.5&nbsp;mmol<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15.0&nbsp;mmol</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23.5&nbsp;mmol<sup>b</sup></p></td></tr></tbody></table><p>a: Value corresponding to the addition of inorganic phosphate.</p><p>b: Including phosphate provided by the lipid emulsion.</p><p>&nbsp;</p><p><em><u>Trace elements and vitamins:</u></em></p><p>Stability has been demonstrated with commercially-available preparations of vitamins and trace elements (containing up to 1 mg of iron).</p><p>Compatibility for other additives is available upon request.</p><p>&nbsp;</p><p>When making additions, the final osmolarity of the mixture must be measured before administration via a peripheral vein.</p><p>&nbsp;</p><p>To perform an addition:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aseptic conditions must be observed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prepare the injection site of the bag.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Puncture the injection site and inject the additives using an injection needle or a reconstitution device.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mix content of the bag and the additives.</p><p>&nbsp;</p><p>Preparation of the infusion</p><p>Aseptic conditions must be observed.</p><p>Suspend the bag.</p><p>Remove the plastic protector from the administration outlet.</p><p>Firmly insert the spike of the infusion set into the administration outlet.</p><p>&nbsp;</p><p>Administration</p><p>For single use only.</p><p>&nbsp;</p><p>Only administer the product after the nonpermanent seals between the 3 compartments have been broken and the contents of the 3 compartments have been mixed.</p><p>&nbsp;</p><p>Ensure that the final emulsion for infusion does not show any evidence of phase separation.</p><p>&nbsp;</p><p>After opening the bag, the contents must be used immediately. The opened bag must never be stored for a subsequent infusion. Do not reconnect any partially used-bag.</p><p>&nbsp;</p><p>Do not connect bags in series in order to avoid the possibility of air embolism due to gas contained in the primary bag.</p><p>&nbsp;</p><p>Any unused product or waste material and all necessary devices must be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Baxter SA
Bd. René Branquart 80
7860 Lessines
Belgium 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12 August 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>